Abstract-Pregnancy-induced hypertension has been suggested to be mediated by several mechanisms, including reduced nitric oxide (NO) synthesis. In this study, the effects of chronic treatment with the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) on blood pressure and the underlying changes in vascular reactivity were investigated in virgin and late-pregnancy Sprague-Dawley rats. The systolic blood pressure was 120Ϯ2, 124Ϯ5, 116Ϯ4, and 171Ϯ5 mm Hg in untreated virgin, virgin treated with L-NAME, untreated pregnant, and pregnant treated with L-NAME rats, respectively. The rats were killed, and the thoracic aorta was cut into strips for measurement of active stress in response to ␣ 1 -adrenergic stimulation with phenylephrine and membrane depolarization by high KCl. In pregnant rats, the maximal active stress to phenylephrine (0.31Ϯ0.03ϫ104 N/m 2 ) and the high-KCl-induced active stress (0.55Ϯ0.09ϫ10 4 N/m 2 ) were smaller than those in virgin rats. By contrast, in the L-NAME-treated pregnant rats, the maximal phenylephrine-induced active stress (0. 76Ϯ0.1ϫ10 4 N/m 2 ) was greater than that in virgin rats (0.52Ϯ0.1ϫ10 4 N/m 2 ), whereas the high-KCl-induced active stress (1.08Ϯ0.14ϫ10 4 N/m 2 ) was indistinguishable from that in virgin rats (1. 03Ϯ0.14ϫ10 4 N/m 2 ). Treatment with L-NAME did not affect the phenylephrine-releasable Ca 2ϩ stores in pregnant rats and had minimal effect on active stress in virgin rats. Thus, reduction of NO synthesis during late pregnancy is associated with a significant increase in blood pressure and vascular responsiveness to ␣-adrenergic stimulation, which can possibly be explained in part by enhanced Ca 2ϩ entry from extracellular space. However, other mechanisms such as increased myofilament force sensitivity to Ca 2ϩ and/or activation of a completely Ca 2ϩ -independent mechanism cannot be excluded. (Hypertension. 1998;31:1065-1069.) Key Words: blood pressure Ⅲ calcium Ⅲ muscle, smooth Ⅲ contraction N ormal pregnancy is associated with many hemodynamic changes such as increased heart rate and cardiac output, 1 increased plasma volume, and an increase in uterine 2-4 and renal blood flow.
1 increased plasma volume, and an increase in uterine [2] [3] [4] and renal blood flow. 5 Despite the increase in heart rate, blood volume, and cardiac output, normal pregnancy is usually associated with a significant decrease in arterial blood pressure and total peripheral resistance. 6 This normal pregnancyassociated decrease in peripheral resistance has been explained by several mechanisms, including an increase in the metabolic requirements of both maternal and fetoplacental tissues and/or a decrease in vascular reactivity. 7 Several explanations have been proposed for the decrease in vascular reactivity during normal pregnancy, such as decreased pressor response to vasoconstrictors, 8 -10 specific alterations within the vascular wall, 11 and an increase in nitric oxide (NO) synthesis. 12, 13 Also, Conrad and Vernier 14 have found that the plasma level, metabolic production, and urinary excretion of cGMP, a second messenger of NO and a cellular mediator of vascular smooth muscle relaxation, are increased during pregnancy.
In 5% to 7% of pregnancies, women develop a condition called pregnancy-induced hypertension. 15 In contrast to normal pregnancy, pregnancy-induced hypertension is characterized by increased arterial blood pressure, generalized vasoconstriction, increased systemic vascular resistance, increased capillary permeability, decreased plasma volume, severe edema, increased intravascular coagulation, reduced tissue perfusion, decreased glomerular filtration rate, proteinuria, and widespread vascular endothelial damage. 15, 16 Although pregnancy-induced hypertension is a leading cause of maternal and fetal mortality, the exact mechanism of this disorder has not yet been clearly identified. Several mechanisms have been suggested, including reduction of NO synthesis 17, 18 and/or changes in the vasoconstrictor receptor affinity or density. 9 Consistent with these suggested mechanisms are reports that chronic NO synthase blockade during mid to late gestation in rats results in many pathological changes similar to those found in women with pregnancyinduced hypertension, such as increased blood pressure, proteinuria, thrombocytopenia, and intrauterine growth retardation. 19 -22 These observations have led investigators to suggest the use of pregnant rats chronically treated with NO synthase blockers as a model to study pregnancy-induced hypertension. 19 -22 Although chronic NO synthase blockade in pregnant rats has been shown to enhance the pressor response to vasoconstrictor substances, 8 it is not clear whether these pressor responses reflect changes in the vascular reactivity. The present study was designed to investigate whether chronic NO synthase blockade in pregnant rats is associated with changes in vascular reactivity. Pregnant rats were treated chronically with N G -nitro-L-arginine methyl ester (L-NAME) during mid to late gestation. L-NAME is a structural analogue of L-arginine and is known to inhibit the synthesis of NO. The L-NAME-induced changes in blood pressure were measured, and the underlying changes in vascular reactivity were investigated for possible alterations in the Ca 2ϩ -handling mechanisms.
Methods

Animals
Female Sprague-Dawley rats (10 to 12 weeks of age) were purchased from Harlan Sprague-Dawley, Inc (Indianapolis, Ind). Rats were divided into four groups: (1) virgin, (2) virgin treated with L-NAME, (3) pregnant, and (4) pregnant treated with L-NAME. The first day of pregnancy was verified by the presence of sperm in vaginal smears (full term is 21 to 22 days). All procedures were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center and the American Physiological Society.
Measurement of Blood Pressure
Systolic blood pressure was measured in the four groups of rats with an automated sphygmomanometer with a tail-cuff device (IITC Life Science Inc). On the day of the experiment (typically 18 to 20 days of gestation in pregnant rats or the equivalent period in virgin rats), pretrained rats were placed in a warm chamber maintained at 30°C for 1 hour, then each rat was transferred to an individual Plexiglas restrainer. The pneumatic tail-cuff device was placed around the rat's tail; at least three pressure measurements were recorded for each rat, and the average systolic blood pressure was calculated.
Tissue Preparation
Rats were terminally anesthetized by inhalation of chloroform. The thoracic aorta was rapidly removed, placed in oxygenated Krebs' solution, and cleaned of connective tissue. The aorta was cut transversely into 3-mm-wide rings. The endothelium was removed by rubbing of the vessel interior with forceps. Rings were cut open into strips. One end of the strip was attached to a glass hook using a thread loop, and the other end was connected to a Grass force transducer (FT03, Astro-Med Inc).
Isometric Tension
Aortic strips were stretched to 2 g of tension and allowed to equilibrate for 1 hour in an organ bath filled with 50 mL Krebs' solution continuously bubbled with 95% O 2 /5% CO 2 at 37°C. The changes in isometric tension were recorded on a Grass polygraph (model 7D, Astro-Med Inc). Removal of the endothelium was routinely verified by the absence of acetylcholine (10 Ϫ6 mol/L)-induced vasorelaxation in aortic strips precontracted with phenylephrine (3ϫ10 Ϫ7 mol/L). Three different protocols were followed in this study. In the first protocol, after the rat aortic strip was allowed to equilibrate for 1 hour, a control contraction was elicited by applying 10 Ϫ5 mol/L phenylephrine to the organ bath solution. Once the phenylephrine contraction reached a plateau, the tissue was rinsed with Krebs' solution three times for a duration of 10 minutes each. The whole procedure of contraction and washing was repeated two times. Phenylephrine was then added cumulatively to the organ bath at concentrations ranging from 10 Ϫ9 mol/L to 10 Ϫ4 mol/L, and the changes in isometric tension were recorded. For each phenylephrine concentration, the contraction was allowed to reach a plateau before the addition of the next concentration.
In the second protocol, control phenylephrine (10 Ϫ5 mol/L) contractions were elicited; then the tissue was incubated in Ca 2ϩ -free (2 mmol/L EGTA) Krebs' solution for 10 minutes. Phenylephrine (10 Ϫ5 mol/L) was added, and the transient phenylephrine contraction in Ca 2ϩ -free solution was recorded. In the third protocol, control contractions were elicited using 96 mmol/L KCl solution, and the tissue was rinsed with Krebs' solution three times for a duration of 10 minutes each. This procedure was repeated two times. Increasing concentrations of KCl solution (16, 24, 36, 51, 66, 78, 86 , and 96 mmol/L) were added to the organ bath separately. Contractions were allowed to reach a steady plateau before the solution was drained and the next concentration of KCl was added.
Solutions
The Krebs' solution contained (in mmol/L) NaCl 120, KCl 5.9, NaHCO 3 25, NaH 2 PO 4 1.2, dextrose 11.5, MgCl 2 1.2, and CaCl 2 2.5. The solution was bubbled with 95% O 2 /5% CO 2 to adjust the pH to 7.4. For the Ca 2ϩ -free Krebs' solution, CaCl 2 was omitted and replaced with 2 mmol/L EGTA. The high-KCl depolarizing solution was prepared as Krebs' solution but with equimolar substitution of NaCl with KCl.
Drugs and Chemicals
The stock solution of phenylephrine (L-phenylephrine hydrochloride; Sigma Chemical Co) was prepared as 10 Ϫ1 mol/L in distilled water. Diluted phenylephrine solutions were also made in distilled water. The L-NAME (Sigma) solution was prepared by adding 50 mg to 1 L of the rat's drinking water. This L-NAME concentration resulted in a daily intake of approximately 1 mg/d. This dose of L-NAME was chosen based on studies of Molnar and coworkers 21 that showed that a dose of approximately 1 mg/d resulted in significant elevation of blood pressure in pregnant rats while having minimal effect in virgin rats. The L-NAME-treated rats were allowed to drink the water containing L-NAME for 4 to 6 days before blood pressure measurements were taken or excision of the aorta. All other chemicals were of reagent grade or better.
Statistical Analysis
The developed force was corrected for the cross-sectional area of each individual strip and expressed as active stress (N/m 2 ) using the following equation: stressϭforce/cross-sectional area, where crosssectional area equals wet weight/(tissue densityϫlength of the strip), and tissue density equals 1.055 g/cm 3 . Data were analyzed and expressed as meanϮSEM. Data were compared using one-way ANOVA with Scheffé's test and unpaired Student's t test. Differences Ͻ.05 were considered statistically significant.
Results
Fig 1 shows the systolic blood pressure recorded in the four groups of rats. In the virgin rats, the systolic blood pressure was 120Ϯ2 mm Hg (nϭ12). The systolic blood pressure of the pregnant rats was slightly lower (116Ϯ4 mm Hg, nϭ17) when compared with the virgin rats. In contrast, the systolic blood pressure of the pregnant rats treated with L-NAME (171Ϯ5 mm Hg, nϭ14) was significantly higher than that in the virgin rats. On the other hand, the systolic blood pressure of the virgin rats treated with L-NAME (124Ϯ5 mm Hg, nϭ12) was not significantly different from that in the virgin rats. Fig 2 shows the contractile response to phenylephrine in rat aortic strips isolated from the four groups of rats. All groups showed a concentration-dependent increase in active stress to phenylephrine. In the virgin rats, phenylephrine (10 Ϫ5 mol/L) produced an active stress of 0.52Ϯ0.10ϫ10 4 N/m 2 (nϭ7). The active stress in the pregnant rats was markedly reduced. In the pregnant rats, phenylephrine (10 Ϫ5 mol/L) produced an active stress of 0.31Ϯ0.03ϫ10 4 N/m 2 (nϭ8). In contrast, the active stress in the pregnant rats treated with L-NAME was markedly increased. In the pregnant rats treated with L-NAME, phenylephrine (10 Ϫ5 mol/L) produced an active stress of 0.76Ϯ0.10ϫ10 4 N/m 2 (nϭ8). On the other hand, active stress in the virgin rats and the virgin rats treated with L-NAME showed no significant difference. In the virgin rats treated with L-NAME, phenylephrine (10 Ϫ5 mol/L) produced an active stress of 0.57Ϯ0.11ϫ10 4 N/m 2 (nϭ8). Fig 3 shows that when the contractile response to increasing concentrations of phenylephrine was presented as a percentage of the maximal phenylephrine contraction, no significant difference among any of the four groups was observed.
Phenylephrine-induced contraction in Ca 2ϩ -free solution is often used as a measure of the phenylephrine-releasable intracellular Ca 2ϩ stores. Fig 4 shows the phenylephrine contraction of rat aortic strips in Ca 2ϩ -free (2 mmol/L EGTA) Krebs' solution. In all groups of rats, phenylephrine showed a transient increase in active stress in Ca 2ϩ -free solution. However, there was no significant difference in the active stress among any of the four groups.
Membrane depolarization by high-KCl solution is known to activate Ca 2ϩ entry through voltage-gated Ca 2ϩ channels. L-NAME (0.94Ϯ0.12ϫ10 4 N/m, 2 nϭ17) and pregnant rats treated with L-NAME (1.08Ϯ0.14ϫ10 4 N/m, 2 nϭ9) was not significantly different from that in the virgin rats.
Discussion
The major findings of this study are that (1) the systolic blood pressure of pregnant rats treated with L-NAME was significantly greater than that of the pregnant rats, the virgin rats, and the virgin rats treated with L-NAME; (2) the vascular reactivity to phenylephrine was decreased in the pregnant rats and increased in the pregnant rats treated with L-NAME when compared with the virgin rats and the virgin rats treated with L-NAME; (3) the transient phenylephrine contraction in Ca 2ϩ -free solution, a measure of the phenylephrine-releasable Ca 2ϩ stores, showed no difference among any of the four groups; and (4) an observed reduced vascular reactivity to membrane depolarization by KCl in pregnant rats was corrected only to the virgin levels when the pregnant rats were treated with L-NAME.
Our results show that systolic blood pressure is slightly lower in pregnant rats than in virgin rats. These results are consistent with the findings of other laboratories. [7] [8] [9] 11, 12, 23 This normal pregnancy-induced drop in blood pressure could be explained by changes in the function of the kidneys, metabolic changes, and/or changes in vascular reactivity. On the other hand, chronic NO synthase blockade with L-NAME caused severe hypertension in pregnant rats. The same dose of L-NAME had minimal effect on blood pressure in virgin rats. These data are consistent with the findings of Molnar and colleagues 21 and further support a role for NO synthase blockade in pregnancy-induced hypertension.
The present study showed that the active stress in response to phenylephrine was greater in the pregnant rats treated with L-NAME than in the pregnant rats. However, since the pregnant rats had a lower blood pressure than the virgin control animals, and the pregnant rats treated with L-NAME showed a significant increase in blood pressure, the possible role of vascular wall remodeling should be considered. Several studies have shown that the increase in blood pressure is often associated with an increase in the thickness of the vascular wall. 24, 25 If this is the case, then the vascular wall thickness is predicted to be greater in the pregnant rats treated with L-NAME than in the untreated pregnant rats. Because the wall thickness was part of the denominator in the "active stress" calculation (N/m2), then the observed increase in active stress in the pregnant rats treated with L-NAME is probably underestimated.
It has been hypothesized that an increase in the production of NO during pregnancy leads to a decrease in peripheral resistance and a decrease in vascular reactivity. 7, 13 If this is the case, one would expect that blocking the formation of NO during pregnancy would bring the vascular reactivity back to the level observed in virgin rats. However, our data show that the vascular reactivity to phenylephrine in pregnant rats treated with L-NAME is greater than that in virgin rats. These results suggest that treatment of pregnant rats with L-NAME not only blocks the synthesis of NO by endothelial cells but may also cause an increase in the synthesis of or sensitivity to other vasoactive compounds that would increase vascular reactivity. It has been suggested that the reduction in the placental blood flow during pregnancy may be associated with placental release of cytotoxic factors that alter the endothelial cell function, leading to reduction in the synthesis of vasodilators such as NO or prostacyclin or, more importantly, increased production of vasoconstrictor factors such as endothelin. 19 -22 This is consistent with a recent study showing that long-term inhibition of NO synthesis during mid to late gestation in rats is associated with increased blood pressure and elevated plasma levels of endothelin-1. 26 The observed increase in vascular reactivity to phenylephrine in pregnant rats treated with L-NAME could be explained by an increase in the sensitivity to phenylephrine at the ␣-adrenergic receptor level. However, our results showed no significant difference between the four groups of rats in the phenylephrine concentration-response curve when the contraction was presented as a percentage of the maximum. These results suggest that the change in the ␣-adrenergic receptor sensitivity to phenylephrine may not be responsible for the observed increase in vascular reactivity in pregnant rats treated with L-NAME and that the increased vascular reactivity could be due to activation of a signaling mechanism downstream from receptor activation.
It is generally accepted that ␣-adrenergic agonists, such as phenylephrine, react with ␣-adrenergic receptors, causing activation of phospholipase C and increased hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol. 27 IP 3 stimulates Ca 2ϩ release from intracellular stores, 28 and diacylglycerol stimulates protein kinase C. 29 In addition, ␣-adrenergic agonists cause plasma membrane Ca 2ϩ channels to open. 30 We tested whether the amount of Ca 2ϩ released from intracellular stores in response to phenylephrine is different in the four groups of rats. We found that the transient phenylephrine contraction in Ca 2ϩ -free solution, which is often used as a measure of phenylephrine-releasable intracellular Ca 2ϩ stores, is not different in the four groups of rats. This suggests that the enhanced vascular reactivity observed in pregnant rats treated with L-NAME is not due to changes in Ca 2ϩ uptake to or Ca 2ϩ release from intracellular stores. To test the possible role of plasma membrane Ca 2ϩ channels in the observed enhanced vascular reactivity to phenylephrine in pregnant rats treated with L-NAME, we tested the effect of KCl, which exclusively stimulates Ca 2ϩ entry through voltage-gated Ca 2ϩ channels. We found that the KCl-induced contraction in the pregnant rats was significantly reduced when compared with that in the virgin rats. These results suggest that normal pregnancy is associated with decreased Ca 2ϩ entry through voltage-gated Ca 2ϩ channels. On the other hand, in the pregnant rats treated with L-NAME, we found that the pregnancy-induced decrease in vascular reactivity to KCl was corrected but only to the level observed in the virgin rats. These results can possibly be explained in part by an increase in the permeability of voltage-gated Ca 2ϩ channels in blood vessels of pregnant rats treated with L-NAME. However, because direct measurements of Ca 2ϩ or myosin light chain phosphorylation were not performed in the present study, we cannot make a definite conclusion that L-NAME treatment increases Ca 2ϩ entry into smooth muscle cells, and other possible mechanisms cannot be excluded. These mechanisms may involve an increase in the myofilament force sensitivity to Ca 2ϩ entry or possibly activation of a completely Ca 2ϩ -independent mechanism. The rebound increase in vascular reactivity to phenylephrine in the pregnant rats treated with L-NAME above that in the virgin rats can then be explained by the following: (1) Phenylephrine may activate an additional group of Ca 2ϩ channels that have a different sensitivity to activation by phenylephrine when compared with the voltage-gated Ca 2ϩ channels. These Ca 2ϩ channels have been found in several smooth muscle preparations and have been designated "receptor-operated Ca 2ϩ channels." 31, 32 (2) Phenylephrine may further activate different pathways that increase the myofilament force sensitivity to Ca 2ϩ or possibly activate a completely Ca 2ϩ -independent pathway. For example, phenylephrine may activate protein kinase C through increased formation of diacylglycerol. 33 In conclusion, the increased blood pressure in late-pregnancy rats treated with L-NAME is associated with an increased vascular reactivity to sympathetic amines. This increased vascular reactivity can possibly be explained in part by an enhancement of Ca 2ϩ entry through Ca 2ϩ channels. However, other mechanisms such as an increase in the myofilament force sensitivity to Ca 2ϩ entry or activation of a completely Ca 2ϩ -independent pathway may also be involved. Further studies are needed to investigate these possible mechanisms.
